Post by CTIN (Clinical Trials Information Network)

A map of European clinical research in metabolism and nutrition disorders - and a few patterns worth noticing. Germany leads with 175 trials, followed by Spain (146) and France (118). No surprises at the top. The middle of the ranking is where it gets interesting. Italy, Poland, the Netherlands and Belgium form a band of countries running between 68 and 107 trials each - a mix of large Western markets and Central European hubs that have quietly become essential to the European trial landscape. Czechia, Denmark and Sweden complete the TOP 10, proving that smaller countries with strong research infrastructure remain highly relevant. Three takeaways: Scale matters, but it is not everything. Central Europe is no longer peripheral in clinical research. Geographic diversity is one of Europe's biggest strengths as a trial destination. For patients, this distribution is good news - access to clinical trials in this therapeutic area is broader than the headlines suggest. 🌍 We are CTIN → Clinical Trials Information Network 𝐖𝐞 𝐛𝐫𝐢𝐝𝐠𝐞 𝐄𝐮𝐫𝐨𝐩𝐞’𝐬 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐞𝐜𝐨𝐬𝐲𝐬𝐭𝐞𝐦 🔍 Follow for clinical research market insights 🤝 Share to support our mission #ClinicalTrials #Metabolism #Europe Novo Nordisk Eli Lilly and Company AstraZeneca Boehringer Ingelheim MSD Merck Sharp & Dohme A.G.